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Neutrophil extracellular traps (NETs), DNA webs released into the extracellular environ-
ment by activated neutrophils, are thought to play a key role in the entrapment and 
eradication of microbes. However, NETs are highly cytotoxic and a likely source of 
autoantigens, suggesting that NET release is tightly regulated. NET formation involves 
the activity of neutrophil elastase (NE), which cleaves histones, leading to chromatin 
decondensation. We and others have recently demonstrated that inhibitors of NE, such 
as secretory leukocyte protease inhibitor (SLPI) and SerpinB1, restrict NET production 
in vitro and in vivo. SLPI was also identified as a NET component in the lesional skin 
of patients suffering from the autoinflammatory skin disease psoriasis. SLPI-competent 
NET-like structures (a mixture of SLPI with neutrophil DNA and NE) stimulated the syn-
thesis of interferon type I (IFNI) in plasmacytoid dendritic cells (pDCs) in  vitro. pDCs 
uniquely respond to viral or microbial DNA/RNA but also to nucleic acids of “self” origin 
with the production of IFNI. Although IFNIs are critical in activating the antiviral/antimi-
crobial functions of many cells, IFNIs also play a role in inducing autoimmunity. Thus, 
NETs decorated by SLPI may regulate skin immunity through enhancing IFNI production 
in pDCs. Here, we review key aspects of how SLPI and SerpinB1 can control NET 
production and immunogenic function.
Keywords: neutrophil extracellular traps, neutrophil elastase, SLPi, serpin B1, plasmacytoid dendritic cells, 
psoriasis
NeUTROPHiL SeRiNe PROTeASeS iN NeUTROPHiL BiOLOGY
Neutrophils, key immune cells for protection against microbial infection, are also associated with a 
range of pathologies, including autoinflammatory diseases, such as systemic lupus erythematosus 
(SLE) and psoriasis (1–3). Neutrophils are a rich source of proteolytic enzymes, including serine 
proteases. The enzymatic activity of serine proteases depends on a catalytic triad that contains a 
serine residue. Four active serine proteases, neutrophil elastase (NE), cathepsin G (CatG), proteinase 
3 (PR3), and neutrophil serine protease 4 (NSP4), as well as azurocidin, an enzymatically inactive 
Abbreviations: CatG, cathepsin G; DPPI, dipeptydyl peptidase I; IFNI, interferon type I; NE, neutrophil elastase; MPO, 
myeloperoxidase; MSU, monosodium urate; PAD4, peptidylarginine deiminase 4; pDCs, plasmacytoid dendritic cells; 
PMA, phorbol ester; PR3, proteinase 3; SLPI, secretory leukocyte protease inhibitor; TFPI, tissue factor pathway 
inhibitor.
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serine protease homolog, were characterized in neutrophils (4, 5). 
Serine proteases are synthesized early in granulocyte develop-
ment, during the promyelocytic stage of granulopoiesis in the 
bone marrow, and require N-terminal trimming by dipeptydyl 
peptidase I (DPPI) for activation (6–8). Under homeostatic condi-
tions, the proteases are stored in a catalytically active form in the 
azurophilic granules of circulating granulocytes (4). Neutrophils 
are equipped with heterogeneous granules, which are classified 
into four subsets: primary or azurophilic granules, formed first 
during granulopoiesis and containing myeloperoxidase (MPO) 
and the serine proteases as their hallmark proteins; secondary or 
specific granules, containing lactoferrin and cathelicidin; tertiary 
or gelatinase granules, with gelatinase and lysozyme; and finally, 
secretory granules, with complement and chemotaxis receptors 
(4, 9). As pre-stored agents, neutrophil serine proteases can be 
quickly engaged to provide protection against microbial chal-
lenge, either by degrading internalized microbes or upon release 
from activated neutrophils. The serine proteases are important 
contributors to the physiological response to infection, both as 
antimicrobial agents and as immunomodulators. Although serine 
proteases, such as NE and CatG, can kill microbes by virtue of 
their antimicrobial activity unrelated to their digestive potential 
(10), these enzymes can also restrain microbial growth through 
the processing of microbial and host proteins. For example, they 
cleave virulence factors of enterobacteria (11) or liberate host anti-
microbial peptides from their inert precursor proteins. The latter 
mechanism was reported for human cathelicidin hCAP-18, which 
is cleaved into the potent antimicrobial peptide LL37 by PR3 (12). 
Serine proteases also participate in a defense against microbes 
through limiting microbial spreading. The underlying mechanism 
involves degradation of an inhibitor of coagulation, tissue factor 
pathway inhibitor (TFPI) by NE, thereby fostering production of 
intravascular fibrin barriers that sequester bacteria (13).
The immunomodulatory function of neutrophil serine 
proteases depends to a large extent on the regulation of the bio-
availability of adhesion molecules, cell surface receptors, growth 
factors, cytokines, and chemoattractants (4). For example, several 
cytokines belonging to the IL1 superfamily, such as IL1β, IL18, 
and IL33, have been reported to be processed into biologically 
active forms by NE, CatG, and/or PR3 (14–16). Given the crucial 
role of these cytokines in inflammatory responses to infection 
or sterile tissue damage, processing of these cytokines alone by 
neutrophil serine proteases may have far-reaching consequences 
for a number of the host defensive strategies. Likewise, by trigger-
ing the chemotactic activity of the inert chemoattractant proteins, 
such as chemerin (17, 18), or increasing the chemotactic potential 
of chemokines, such as CXCL8 (19), neutrophil serine proteases 
may mobilize specific immune cells to sites of inflammation. On 
the other hand, the NE-mediated proteolytic degradation of the 
chemokine CXCL12 and its receptor CXCR4, which disrupts 
the CXCL12/CXCR4 chemotactic pathway in the bone marrow, 
facilitates the mobilization of hematopoietic stem cell precur-
sors from the bone marrow into the circulation in response to 
mobilizing agents, such as G-CSF (20). Together, these findings 
indicate that by activating or deactivating cell-guiding molecules, 
the serine proteases provide an important layer of control over 
cell recruitment.
The enzymes also influence neutrophil development and the 
functional state of the cell, including apoptosis and the formation 
of neutrophil extracellular traps (NETs). Mutations in the gene 
encoding NE-ELANE are a leading cause of severe congenital 
neutropenia (SCN), a disorder leading to a lack of mature neu-
trophils (21, 22). However, pathogenic ELANE mutations are 
distributed throughout NE, and at least some ELANE mutants 
retain NE activity (23), indicating that neutropenia is not a result 
of impaired NE proteolytic function. Indeed, recent advances 
suggest that the pathogenesis of ELANE mutations is associated 
with NE mislocalization, the accumulation of NE in the ER and 
other cytosolic regions outside of the azurophilic granules, and 
the activation of the unfolded protein response/ER stress. These 
alterations in turn lead to the death and differentiation arrest of 
granulocytic precursors (promyelocytes). Notably, the sequestra-
tion of mutated NE in azurophilic granules of myeloid precursor 
cells, as well as neutrophil maturation, can be rescued by a small, 
cell-permeable NE inhibitor, sivelestat, given in combination 
with low-dose G-CSF (23). Although sivelestat may also affect 
cellular responses in a manner independent of NE inhibition (24), 
these findings suggest that a NE inhibitor protects differentiating 
granulocytes against the activity of the mislocalized NE and that 
the impaired intracellular trafficking of NE can be corrected in 
the presence of a NE inhibitor.
Neutrophils have a short life span relative to other cells and 
are subjected to caspase-3-mediated spontaneous death, which 
phenotypically fits the profile of apoptotic cell death (25). 
Apoptosis is triggered and executed via intracellular cysteine 
proteases-caspases. The main effector protease that drives the 
terminal stages of cell death is caspase-3. This protein requires 
proteolytic cleavage for apoptotic activity. Among the key activa-
tory enzymes are caspase-9 and caspase-8. It was recently reported 
that although cleavage of caspase-3 was integral to the death of 
aging neutrophils, it was independent of the proteolytic activity 
of caspase-8 or caspase-9. Instead, PR3 leaking from azurophilic 
granules into the cytosol was found to regulate caspase-3 activa-
tion and cell death in aging neutrophils (25).
Similar to apoptosis, neutrophil serine proteases have been 
shown to contribute to the formation of NETs. This process, 
called NETosis, is associated with irreversible cell state changes, 
but in a manner distinct from apoptotic death (26).
ROLe OF SeRiNe PROTeASeS  
iN NeT FORMATiON
Neutrophil extracellular traps are web-like DNA structures 
extruded into the extracellular environment by activated neutro-
phils. A wide range of stimuli triggers NETosis, including Gram-
positive and Gram-negative bacteria, such as Staphylococcus 
aureus (26, 27) and Shigella flexneri (28); the fungus Candida 
albicans (29); parasites, such as Leishmania amazonensis (30); 
and viruses, such as HIV-1 (31). NET formation is also induced 
by host-derived inflammatory mediators, such as hydrogen 
peroxide (H2O2) (26), the cytokines, such as IL17 and TNFα 
(32), chemokines, such as CXCL8 (28), monosodium urate 
(MSU) (33), cholesterol (34) or calcium carbonate crystals (35), 
antibodies (36), or antibody–antigen complexes (2). Synthetic 
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chemicals, such as phorbol ester (PMA) or ionophores, are the 
most potent inducers of NETosis commonly used in experimen-
tal systems.
Neutrophil extracellular traps are thought to represent 
a unique defense strategy against microbial infection. NET 
microbicidal function is aided by antibacterial proteins and 
peptides that are complexed with decondensed chromatin and 
mitochondria-derived DNA. These proteins include histones, 
which account for ~70% of all detected proteins in PMA-
stimulated neutrophils, as well as serine proteases. Notably, NE 
is the most abundant non-histone NET-protein, accounting 
for ~5% of the total protein (29). In agreement with the high 
levels of NE in NETs revealed by proteomic analysis, a dominant 
role was also found for the NE-mediated proteolytic signature 
in NETs based on a functional activity assay (37). Whereas the 
major proteolytic activity associated with NETs derived from 
PMA-stimulated neutrophils was attributed to NE (~70%), all 
remaining neutrophil serine proteases (CatG, PR3, and NSP4), 
most notably CatG, contributed to the cleavage sites that were 
profiled in NET samples (37). These data suggest the proteolytic 
involvement of all neutrophil serine proteases in NET formation 
and/or function.
The mechanisms that underlie NET release are not yet fully 
characterized but are proposed to involve at least two strategies. 
One pathway can be triggered by specific microbes or PMA, takes 
2–4 h to culminate in NET release, and is associated with plasma 
membrane perforation and neutrophil cell death (26). After acti-
vation, neutrophils undergo step-wise morphological changes, 
including chromatin decondensation, nuclear expansion, and 
nuclear envelope disintegration, which is followed by the intracel-
lular assembly of nuclear and cytoplasmic components. Finally, 
DNA coated with nuclear and cytoplasmic proteins is deposited 
into the environment following plasma cell rupture and cell 
lysis (26). In the other pathway, neutrophils undergoing NET 
formation can extrude a fraction or their entire nuclear DNA 
mainly through nuclear budding and vesicular release. During 
this process, neutrophils can maintain their integrity and live 
cell function, such as migration and phagocytosis, at least for a 
couple of minutes when tested in vivo (38). This form of non-
lytic NET extrusion, also known as vital NETosis, is triggered by 
complement-opsonized targets and occurs much more rapidly 
(<30  min). Since NET release that involves cell lysis is a slow 
process, potentially allowing microbes to exploit the open time 
window for infection, the rapid NETosis might prove particularly 
beneficial against infection (38).
However, rapid NET release by neutrophils was also reported 
in response to collagen-activated platelets as well as danger 
signals, such as MSU crystals (13, 33, 39), suggesting that rapid 
NETosis is not limited to microbes. Platelet and neutrophil 
dialog through NETs supports blood clotting (13, 40). NETs that 
are formed within the vasculature capture anticoagulants, such 
as TFPI, enabling proteolytic inactivation of TFPI on NETs by 
NE. As a consequence of TFPI degradation, fibrin formation is 
rapidly enhanced (13). NETs are not only induced by activated 
platelets but can also serve as a scaffold to platelets aggregation 
and red blood cells adhesion, thereby accelerating coagulation 
(40). On the other hand, MSU crystal deposits in joints can 
induce gouty arthritis. These MSU crystals required 10 min to 
trigger NETosis and NET aggregation in human neutrophils 
(33). Aggregated NET structures were formed when neutrophils 
at high densities were stimulated with the crystals, mimicking 
dense neutrophil infiltrates in the synovial fluid of individuals 
with gouty arthritis. The aggregation of NETs was found to be 
beneficial in the setting of inflammatory arthritis, since it pro-
moted degradation of chemokines and cytokines, such as IL1β, 
that were entrapped in NETs, providing a potential mechanism 
for resolution of inflammation (33). Thus, rapid NETosis may 
potentially serve multiple functions.
One of the best characterized models of NET formation is 
based on the activation of neutrophils purified from human 
blood by PMA. The model depends on the production of reac-
tive oxygen species (ROS) by the NADPH oxidase complex 
and involves NE as one of the major contributors to chromatin 
decondensation (41, 42).
Several lines of evidence support the critical involvement 
of NE in NET generation. First, inhibitors of NE proteolytic 
activity, such as small β-lactam-based, cell-permeable NE 
inhibitors, blocked chromatin decondensation and NET release 
in neutrophils derived from healthy volunteers (41). Moreover, 
neutrophils isolated from patients suffering from Papillon–
Lefevre syndrome (PLS) failed to release NETs or were severely 
impaired in NET formation (43, 44). PLS is a disorder caused by 
loss-of-function mutations in the gene encoding DPPI, resulting 
in marked defects in the activities of serine proteases, including 
NE (43). Finally, NETs were not detected in the lungs of mice 
deficient in NE in a pulmonary model of Klebsiella pneumoniae 
infection (41) or in mice double-deficient in NE and PR3 in an 
experimental model of atherosclerosis (34). Although mouse 
neutrophils are much less prone to NET formation than human 
granulocytes, together, these data indicate that the genetic or 
functional deficiency of NE severely inhibits NETosis. However, 
the lack of NE did not prevent NET generation in an experi-
mental model of deep vein thrombosis (24). These data suggest 
that NE, although linked to NETosis, is not a causative agent 
in this process, or that neutrophils do not exclusively rely on 
NE for NET formation. Indeed, chromatin decondensation, a 
critical step in NETosis, was reported to also be mediated by 
peptidylarginine deiminase 4 (PAD4). Whereas NE destabilizes 
chromatin structure via the processing of specific histones (41), 
PAD4 mediates chromatin decondensation through converting 
histone tail arginine residues to citrullines (45). PAD4 is the 
main PAD isozyme expressed in neutrophils out of five PADs 
present in human cells. Moreover, histone citrullination is 
catalyzed primarily by PAD4, whereas other PADs citrullinate 
multiple substrates out of the nucleus (46). These data suggest 
that chromatin decondensation and subsequent NETosis relies 
mainly on PAD4.
Although the relative contribution of NE and PAD4 to 
histone modification and the alteration of chromatin structure 
in NETosis remain to be determined, it is likely that both 
enzymes act as co-regulators or separate regulators of chromatin 
decondensation, depending on the type of NET stimulus. For 
example, PAD4 requires calcium for its enzymatic activity (47), 
and NETosis triggered by calcium influx is associated with the 
TABLe 1 | The main characteristics of SerpinB1 and SLPi.
Main 
expression
Main 
localization
Main  
functions
Proteolytic 
targets in 
neutrophils
SerpinB1 Macrophages, 
neutrophils
Intracellular Inhibitor of serine 
proteases, DNAse
NE, CatG, 
PR3
SLPI Epithelial cells, 
neutrophils
Secreted Inhibitor of serine 
proteases, 
Antimicrobial protein, 
Inhibitor of NFκB
NE, CatG
4
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presence of citrullinated histones, such as citrullinated histone 
H3, in the activated neutrophils (48, 49). However, in contrast 
to the calcium ionophore-stimulated granulocytes, citrullinated 
histone H3 was hardly observed in neutrophils triggered to form 
NETs by PMA, suggesting that PAD4 is less required for the 
PMA-regulated NETosis pathway (24, 42).
As mentioned earlier, NE is confined to azurophilic granules 
in resting neutrophils. However, upon neutrophil activation, 
NE can translocate to the nucleus and aid in chromatin decon-
densation via core histone cleavage (41). NE translocation from 
the primary granules to the nucleus is dependent on ROS gener-
ated by NADPH oxidase and MPO, which assists in releasing 
active NE from the granules into the cytosol (50). According 
to the recently proposed model of NE translocation, NE in 
azurophilic granules is associated with several other granule 
proteins, including MPO, PR3, CatG, azurocidin, eosinophil 
cationic protein, defensin-1, lysozyme, and lactoferrin. This 
association is supported by the immunoprecipitation of these 
proteins with anti-NE antibodies from isolated and detergent-
solubilized azurophilic granules. H2O2, the secondary product 
of NADPH oxidase, triggers the dissociation of the NE protein 
complex from intact azurophilic granules, releasing NE when 
the enzyme is still assembled with CatG and azurocidin. In 
the cytoplasm, NE binds to the actin cytoskeleton and pos-
sibly degrades F-actin to reach the nucleus (50). Notably, the 
accumulation of NE in the insoluble cytoskeleton fraction 
isolated from the activated neutrophils is facilitated in the 
presence of a small molecule inhibitor of NE. Because block-
ing of NE activity markedly reduces NE entry into the nucleus 
(41), together, these findings are consistent with the model in 
which active NE interacts with the cytoskeleton en route to 
the nucleus and the inhibition of NE activity arrests NE on the 
cytoskeleton, preventing NE from translocating to the nucleus 
(50). Defining F-actin as a potential cytoplasmic substrate for 
NE also indicates that this protease may regulate neutrophil 
migration via the disassembly of the actin cytoskeleton during 
NETosis. NE interference with actin dynamics is likely to disable 
cell movement and confine NETting neutrophils to the NET 
trigger site. This strategy, embraced by neutrophils undergo-
ing PMA- or C. albicans-induced NETosis, differs considerably 
from the rapid, vital NETosis that coexists with the ability of 
neutrophils to crawl (38, 50). Although these differences imply 
that NE might not be involved in rapid NETosis, early NET 
release that occurred 10 min after neutrophil stimulation with 
L. amazonensis was reduced by a NE inhibitor but was not 
significantly affected by diphenyleneiodonium (DPI), which 
mainly inhibits NADPH oxidase-mediated ROS production 
(30). These data suggest that NE might also be involved in rapid, 
ROS-independent NETosis.
iNHiBiTORS OF SeRiNe PROTeASeS 
iN NeT GeNeRATiON
Small molecule, exogenous NE inhibitors suppressed NET for-
mation, suggesting that endogenous inhibitors of serine proteases 
might regulate NETosis in similar fashion. Notably, neutrophils 
contain multiple serine protease inhibitors (51, 52), but the roles 
of SerpinB1 and secretory leukocyte protease inhibitor (SLPI) are 
the best known in the context of neutrophil function (52, 53).
SeRPiNB1
SerpinB1, also known as leukocyte elastase inhibitor (LEI) or 
monocyte/NE inhibitor (MNEI), is a member of the serpin 
family of serine protease inhibitors. Serpins are proteins char-
acterized by a unique tertiary structure that employs a suicide-
substrate-like mechanism to deactivate their target proteases 
(54). The inhibitors expose their reactive site loop as a substrate 
for a cognate protease. The protease cleaves the loop, which leads 
to extensive conformational changes of the serpin, resulting in 
protease entrapment in a tight covalent complex (55). Human 
serpins are divided into nine clades, named from A to I (56). 
SerpinB1 is a 42-kDa protein and is a member of the clade B 
serpins. Among the neutrophil serine proteases, SerpinB1 
inhibits NE, PR3, and CatG. Notably, SerpinB1 is one of the most 
efficient inhibitors of NE (57, 58). SerpinB1 is mainly expressed 
in macrophages and neutrophils and accumulates at high levels 
in the cytoplasm and granules of neutrophils (59). It lacks a signal 
peptide and is not secreted to the extracellular environment via 
the classic secretory pathway. However, the detection of SerpinB1 
in extracellular localizations, possibly as a result of cell necrosis, 
was also reported (60, 61).
This multifunctional cytoplasmic protein acts as a protease 
inhibitor in its native form, but the cleavage of SerpinB1 by its 
cognate proteases can lead to the loss of antiprotease properties 
and gaining other functions, such as DNAse activity. A SerpinB1 
derivative equipped with nuclease activity, called L-DNAse II, 
was isolated from porcine spleen (62). NE-mediated SerpinB1 
conversion from an antiprotease to an endonuclease resulted 
from conformational alteration that exposed the endonuclease 
active site and a nuclear localization signal. The SerpinB1 
derivative L-DNAse II was reported to have pro-apoptotic 
effects (63). The main features of SerpinB1 are summarized in 
Table 1.
By contrast, data have been accumulating that SerpinB1 plays 
a pro-survival role in neutrophils. This role is exemplified by the 
recently reported regulation of the spontaneous death of aging 
neutrophils by SerpinB1, via counterbalancing the activity of PR3 
during leakage of the protease from azurophilic granules (25). 
Whereas cytosolic SerpinB1 was found to form a complex with 
PR3 in neutrophils undergoing spontaneous death but not in 
freshly isolated neutrophils, the rate of spontaneous death was 
increased in neutrophils isolated from SerpinB1-deficient mice 
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(25). These findings are consistent with the protective role of 
SerpinB1 against apoptosis.
An intrinsic defect in survival observed in neutrophils 
derived from SerpinB1 knock-out mice may also be caused 
by a higher propensity of these cells to die by NETosis. In a 
model of Pseudomonas aeruginosa lung infection, neutrophils 
infiltrating the lungs of SerpinB1-deficient mice exhibited 
excessive death. The cell death was accompanied by the pres-
ence of free NE, MPO, and DNA in the bronchoalveolar lavage 
fluid (BALF) (52). In ex vivo experiments, neutrophils devoid 
of SerpinB1 that were isolated from the BALF of the infected 
mice also generated more NETs than those from control mice. 
These findings demonstrated that NETosis was increased in 
SerpinB1-deficient mice in the setting of infection. Higher 
susceptibility of SerpinB1-deficient neutrophils to form NETs 
was also found when neutrophils isolated from the bone mar-
row of uninfected mice were subjected to treatment with native 
proinflammatory mediators, such as the chemokine CXCL2, 
or PMA, suggesting that SerpinB1 controls NETosis (52). The 
addition of recombinant SerpinB1, but not related serpins, to 
these in vitro activated neutrophils abrogated NET production 
(52). These findings indicated that SerpinB1 is a negative 
regulator of NETosis.
In response to PMA, SerpinB1-deficient mouse neutrophils 
demonstrated a higher tendency to expand their nuclei, indica-
tive of chromatin decondensation. Moreover, in PMA-treated 
human neutrophils, SerpinB1, similar to NE, migrated to the 
nucleus and co-stained with NE and DNA on NETs formed 
by the stimulated cells. These results raised the possibility 
that SerpinB1 blocks NET formation via interfering with 
NE-mediated chromatin decondensation. However, SerpinB1 
localization to the nucleus did not seem to involve forming a 
complex with NE. When NE was confined to the cytoplasmic 
region by neutrophil pretreatment with a chemical protease 
inhibitor, SerpinB1 could still translocate to the nucleus (52). 
Moreover, the enhanced NET formation observed in SerpinB1-
deficient mice was not reversed by NE deletion (24). Therefore, 
NE might not be an exclusive SerpinB1 target in restricting 
NETosis. Given the multiplicity of its cognate proteases, it is also 
possible that, in the absence of NE, SerpinB1 might select other 
proteolytic targets to limit NET generation. As an alternative 
mechanism, nuclear SerpinB1 was proposed to interfere with 
PAD4 by blocking PAD4 access to histone tails (52). This role for 
SerpinB1 in regulating chromatin decondensation is supported 
by the ability of the inhibitor to tightly associate with condensed 
chromatin (64).
Secretory Leukocyte Protease inhibitor
Secretory leukocyte protease inhibitor, a single polypeptide cati-
onic protein of 107 amino acids, is also known as antileukopro-
tease (ALP), bronchial secretory inhibitor (BI), human seminal 
inhibitor I (HUSI-I), cervix uterine secretion inhibitor (CUSI), 
mucous proteinase inhibitor (MPI), or secretory leukoprotease 
inhibitor (SLI) (65). The most well-documented role of SLPI 
is the inhibition of serine proteases, including human NE and 
CatG but not PR3 (66), Table 1. Beyond a role in neutralizing 
proteases, SLPI is also microbicidal and suppresses the activity 
of the transcription factor NFκB (67). SLPI is a canonical type 
of serine protease inhibitor, binding to proteases through the 
exposed binding loop, which in conformation is complementary 
to the enzyme’s active site (66). The inhibitor is composed of 
two four-disulfide core domains, also called whey acidic protein 
(WAP) domains. The N-terminal WAP I and C-terminal WAP II 
domains share 35% homology (68), but their biological function 
is distinct. The WAP II domain is primarily responsible for the 
antiprotease activity of the SLPI. The biological function of the 
N-terminal WAP I domain is less well understood, although the 
antimicrobial potential of SLPI is thought to mainly reside in this 
domain (67).
In contrast to SerpinB1, SLPI is predominantly secreted and 
found primarily at mucosal surfaces as a product of epithelial 
cells. The inhibitor is also expressed in leukocytes, including 
neutrophils, macrophages, and dendritic cells (67). Despite the 
presence of a signal peptide, indicative of cell secretion, SLPI 
has intracellular targets, suggesting that it might be retained in 
cells. However, the inhibitor can penetrate cellular membranes 
and potentially be acquired from adjacent cells. Such loading 
with SLPI, mimicked in experimental systems by cell treat-
ment with the exogenous inhibitor, appears to be functionally 
relevant. For example, SLPI produced by epithelial cells lining 
tonsillar crypts restrains the production of antibodies in adja-
cent B cells (69).
Although SLPI was shown to inhibit a wide spectrum of 
proteases, one of its main actions is likely to be the inhibition of 
NE because the complex of SLPI with NE is the strongest among 
complexes of SLPI with any other proteases (66, 70). Notably, 
SLPI is thought to be the major inhibitor of NE present in the 
neutrophil cytosol (51). According to another report, SLPI is 
primarily stored in secondary granules in neutrophils (71). As 
SLPI, similar to NE, is likely to migrate between different cell 
compartments in response to neutrophil stimulation, the pres-
ence of SLPI in the cytosol or in specific granules might reflect 
different activation statuses of neutrophils. The main features of 
SLPI are summarized in Table 1.
Secretory leukocyte protease inhibitor plays a regulatory 
role in granulopoiesis (72) and, similar to SerpinB1, inhibits 
apoptosis in circulating neutrophils (73). The mechanism 
underlying its antiapoptotic activity remains to be determined. 
However, the protective role of SLPI in apoptosis might be 
reminiscent of SerpinB1 counteracting PR3, although its activ-
ity must be directed against other proteases because SLPI does 
not inhibit PR3.
Secretory leukocyte protease inhibitor may also serve to protect 
cells from the harmful effects of NETosis. This conclusion stems 
from the observation that stimulation of human neutrophils with 
PMA, TNFα, or S. aureus in the presence of exogenous SLPI, but 
not another native NE inhibitor, α1-proteinase inhibitor, substan-
tially decreased NET release. Exogenous SLPI mainly localized to 
the cytoplasm of resting neutrophils, but upon stimulation it relo-
cated to the nucleus and inhibited histone cleavage. Endogenous 
SLPI was also found to co-localize with NE in the nuclei of 
in vitro activated human neutrophils, or in neutrophils infiltrat-
ing the skin of patients with the autoinflammatory skin disease 
psoriasis (53). Together, these data suggested that the protective 
6Majewski et al. SLPI and SerpinB vs. NETs
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 261
effect of SLPI in NET formation might result from constraining 
NE-mediated histone processing. Notably, although histone 
cleavage was efficiently blocked by added SLPI independently of 
the NET-triggering stimulus, in response to PMA, neutrophils 
appeared to degrade more histones than neutrophils stimulated 
with S. aureus (53). This observation further points to divergent 
mechanisms underlying NETosis, with S. aureus possibly relying 
more on other pathways. Moreover, the inhibition of NE activity 
was unlikely to be solely responsible for the SLPI tailoring effect 
on NETosis because SLPI mutants devoid of inhibitory activity 
against NE were still capable of restraining NET formation in 
stimulated neutrophils, albeit to a lower degree than the fully 
active SLPI (53). Given the inhibitory effects of SLPI against 
multiple proteolytic enzymes, one possible mechanism whereby 
SLPI may interfere with NETosis is to counteract other proteases. 
In another scenario, the independent antiprotease activity of SLPI 
might be involved in blocking NET release. In agreement with 
the anti-NET effect of SLPI, the inhibitor deficiency led to exces-
sive NETosis in in vitro activated bone marrow neutrophils. The 
negative regulation of NET formation by SLPI was further sup-
ported by an in vivo psoriasis model. This model demonstrated 
that SLPI−/− neutrophils infiltrating psoriatic skin formed twice as 
many NETs as WT neutrophils (53).
Because neutrophil treatment with exogenous SLPI resulted 
in a partial decrease in NET generation, other inhibitory parallel 
pathways must exist. The overlapping but distinct activities of 
SLPI and SerpinB1 against neutrophil proteases (Table  1), as 
well as the structural and functional heterogeneity between the 
inhibitors, suggest that SLPI and SerpinB1 may act in synergy to 
control NETosis.
iNHiBiTORS OF SeRiNe PROTeASeS 
iN NeT FUNCTiON
Uncontrolled NET production in chronic inflammatory states 
has serious consequences. For example, NET formation may 
contribute to the pathogenesis of autoimmune diseases, as 
NETs are cytolytic and are a potential source of autoantigens 
(32, 74, 75). Multiple NET components, including DNA, 
histones, MPO, PR3, LL37, CatG, and NE, are recognized by 
autoantibodies (76–78). The clinical measures of disease sever-
ity are often positively correlated with the titers of antibodies 
directed against NET components (79). As discussed earlier, 
SerpinB1 and SLPI may be a part of the defense system to 
cope with challenges imposed on the host by NET deposition. 
However, as regulators of NETosis, they may be externalized 
together with other NET components and impact immunity 
after extrusion from neutrophils. Although SLPI, as a secretory 
protein, is unlikely to be intrinsically immunogenic, intracellular 
SerpinB1, normally hidden in the cell, might be revealed as a 
consequence of NETosis and potentially provoke or enhance 
immune responses. Immunohistochemistry data indicated that 
in vitro activated human neutrophils release NETs with SerpinB1 
and SLPI attached to DNA (52, 80). Likewise, SLPI was also 
found to decorate NETs in the affected skin of patients suffering 
from psoriasis (80, 81), suggesting that the presence of SLPI on 
NETs might be functionally relevant.
Psoriasis is a skin condition affecting on average 2–3% of 
the population all over the world (82). Most often, it manifests 
as erythematous cutaneous lesions covered with silvery scales. 
The disease is incurable and although it is not life threatening 
on its own, patients suffering from psoriasis exhibit a higher risk 
of developing comorbidities, such as other autoimmune disor-
ders, metabolic syndrome, and cardiovascular disease (83, 84). 
On a cellular level, psoriasis is characterized by dysfunctional 
keratinocyte proliferation and differentiation, as well as inflam-
mation elicited by abundant immune cells that are rare or absent 
in healthy skin (85). Among them are plasmacytoid dendritic 
cells (pDCs) and neutrophils. Although emerging data indicate 
that chronic inflammation in this disease is mediated primarily by 
Th17 cells and their signature product, IL17 (86), the pathologi-
cal events underlying the initiation of the disease are much less 
understood (87). pDCs accumulate early in psoriatic skin lesions 
or pre-lesional skin adjacent to affected skin (85, 88), suggesting 
that pDCs are well-placed to contribute to early skin alterations. 
These cells are considered key producers of interferon type I 
(IFNI) (89). pDCs and IFNI were implicated in the pathogenesis 
of psoriasis and other autoimmune diseases, such as SLE (90, 
91). The diseases exhibit broad activation of IFNI pathways (1). 
Direct evidence for a pathogenic role for pDC-derived IFNI in 
psoriasis is provided by a human/mouse skin xenograft model. 
In this model, the spontaneous conversion of the transplanted 
human uninvolved (normal appearing) skin of psoriasis donors 
into psoriatic skin lesions is prevented by blocking IFNI signaling 
or inhibiting pDC production of IFNI (92). As one of the key cell 
types involved in antiviral immunity, pDCs are well equipped with 
intracellular sensors of nucleic acids, such as TLR7 and TLR9, 
which recognize single-stranded RNA and DNA, respectively 
(89). However, pDCs can be activated in a TLR-dependent man-
ner, not only by foreign but also by self RNA and DNA. In each 
case, pDC stimulation can lead to the production of IFNI and 
IFNI-driven immunity (93, 94). To be functional ligands for TLRs, 
host nucleic acids need to be of mitochondrial origin and/or form 
complexes with specific proteins, such as antimicrobial LL37 (93, 
94) or NE together with SLPI (80). Notably, activated neutrophils 
are a likely source of these IFNI-triggering factors because they 
extrude both oxidized mitochondrial nucleoids (95, 96) and 
nuclear DNA decorated with the proteins (3). Mitochondria, 
along with the phagosome-localized NADPH oxidase complex, 
are major sites of ROS production, and mitochondrial DNA is 
highly susceptible to oxidation (97). This modification is required 
for the potent interferogenic potential of mitochondrial DNA 
(95). Although mitochondrial DNA can be extruded from cells 
without subsequent cell death and release of nuclear DNA (98), it 
is likely that neutrophils triggered by a suitable stimulus co-release 
oxidized mitochondrial and chromosomal DNA. This possibility 
is supported by recent findings that demonstrate that NETs are 
enriched in oxidized mitochondrial DNA when stimulated with 
ribonucleoprotein immune complexes (96). Therefore, unique 
structural or functional assets of host DNA, such as levels of 
oxidized mitochondrial DNA in the NET structure, and/or other 
NET DNA modifications, possibly resulting from the specific 
assembly of DNA with neutrophil proteins, may allow pDCs to 
recognize self DNA.
FiGURe 1 | Proposed involvement of SerpinB1 and SLPi in NeT 
formation and immunogenic function. (1) In resting neutrophils, NE 
localizes to primary granules, whereas SerpinB1 and SLPI localize to the 
cytoplasm and/or secondary granules. (2) In activated neutrophils that infiltrate 
psoriatic skin, NE translocates to the nucleus, where it contributes to 
chromatin decondensation. SLPI and SerpinB1 translocate independently to 
the nucleus, where they regulate NET formation at the level of chromatin 
decondensation. Once in the nucleus, SLPI restricts the NE-mediated cleavage 
of histones, whereas SerpinB1 limits chromatin decondensation through other, 
yet-to-be-identified mechanisms. (3) The inhibition of NET formation is partial, 
and the decondensed chromatin containing NE, as well as SerpinB1 and SLPI, 
is deposited into the extracellular milieu. (4) SLPI produced by keratinocytes in 
lesional psoriatic skin is sequestered on NETs. (5) SLPI-competent NETs 
stimulate the pro-inflammatory and/or skin healing function that results from 
skin damage through the production of IFNI by pDCs.
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In psoriatic skin, induction of IFNI synthesis by 
 neutrophil-derived self DNA in skin-infiltrating pDCs may 
depend on SLPI. Some insights into this came from the observa-
tion that NET-like structures, consisting of DNA, NE, or CatG, 
and SLPI were present in the affected skin of patients with 
psoriasis (80, 81). Moreover, pDCs were found to locate in close 
proximity to neutrophils and NETs (80), indicating that pDCs 
and SLPI-decorated NETs might be linked in controlling skin 
pathophysiology. Although not effective on its own, SLPI in com-
plex with neutrophil DNA and its cognate enzymes, NE or CatG, 
induced a marked increase in the production of IFNI by pDCs 
(80, 81). This response was mediated by TLR9, suggesting that 
recognition of self DNA by intracellular TLR9 and/or activation 
of the receptor is facilitated by SLPI. Other inhibitors exposed on 
NETs can potentially also be involved in the stimulation of IFNI 
production in pDCs. Although the role of SerpinB1 in this process 
remains unknown, SLPI appears to have the selective capacity 
to induce the expression of IFNI in pDCs. In contrast to SLPI, 
neither the main plasma inhibitor of NE, α1-proteinase inhibitor, 
nor the main plasma inhibitor of CatG, α1-antichymotrypsin 
(99, 100), were effective at stimulating IFNI production by pDCs 
(80, 81). Therefore, regulation of the catalytic activity of serine 
proteases may not be a uniting or adequate property for an inhibi-
tor to enable pDCs to produce IFNI. This possibility was further 
supported by the finding that SLPI lacking potent anti-NE activity 
was still equipped with pDC-stimulating functions. By contrast, 
the proimmunogenic ability of SLPI together with DNA and NE 
required enzymatically active NE because NE inhibited by a small 
synthetic inhibitor, or another inactive protein closely related to 
NE and embedded in NETs, azurocidin, did not stimulate pDCs 
to produce IFNI (80). The proimmunogenic properties of SLPI 
may primarily be related to its cationic nature because cationic 
peptides, such as LL37, display strong capacity to activate pDCs 
(101). However, cationicity alone does not appear to be sufficient 
for the stimulation of IFNI production in pDCs because the com-
plex of SLPI and neutrophil DNA was unable to potently trigger 
IFNI production by pDCs (80).
A role for SLPI in psoriasis was initially suggested by the 
observation that SLPI is markedly upregulated in the epidermis 
of psoriasis patients, particularly in keratinocytes (102). As 
described previously, neutrophils are a potential but not neces-
sarily unique source of SLPI on NETs in psoriatic skin. Given 
the ability of SLPI to bind to DNA (103), it can be envisaged that 
SLPI produced by keratinocytes might dock to NETs deposited 
in psoriatic skin via skin-infiltrating neutrophils (Figure 1). In 
principle, NETs enriched in SLPI might be particularly suitable to 
prime pDC responses. NETs different in composition or protein 
levels were described earlier. Although the protein constitution 
in NETs might be influenced directly by the triggering stimulus 
(32), it is also likely that the stimulatory power of NETs may 
depend on the tissue context, by recruiting additional tissue-
specific components to the externalized nuclear/mitochondrial 
nucleic acids.
The functional significance of SLPI on NETs in psoriasis 
remains to be determined. However, SLPI might be involved 
in several levels of NET regulation in inflamed skin, each 
potentially leading to different outcomes. As a NET component, 
SLPI is likely to have an impact on the production of IFNI by 
pDCs, facilitating IFNI-mediated immune and skin healing 
responses (67). The  flipside is the generation of a potentially 
harmful stimulus (SLPI-decorated NETs) that can increase the 
risk of autoimmune inflammation. On the other hand, the ability 
of SLPI to inhibit NETosis in neutrophils makes it ideally suited 
for serving as a safeguard against the harmful effects of NETs. 
Either way, SLPI emerges as an important participant in innate 
immunity via the regulation of NET generation and immuno-
genic function (Figure 1).
AUTHOR CONTRiBUTiONS
All authors listed have made substantial, direct, and intellectual 
contribution to the work and approved it for publication.
FUNDiNG
This work was supported by Polish National Science Center grant 
2011/02/A/NZ5/00337 (to JC). The Faculty of Biochemistry, 
Biophysics, and Biotechnology of the Jagiellonian University is 
a beneficiary of the structural funds from the European Union 
(grant No: POIG.02.01.00-12-064/08) and a partner of the 
Leading National Research Center (KNOW) supported by the 
Polish Ministry of Science and Higher Education.
8Majewski et al. SLPI and SerpinB vs. NETs
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 261
ReFeReNCeS
1. Cichy J, Zabel BA. Proteinase regulators of plasmacytoid dendritic cell traf-
ficking and function in psoriasis. In: Carrasco JA, editor. Psoriasis: Causes, 
Diagnosis and Treatment. New York: Nova Science Publishers, Inc. (2011). 
p. 137–57.
2. Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, et  al. 
Netting neutrophils are major inducers of type I IFN production in pediatric 
systemic lupus erythematosus. Sci Transl Med (2011) 3:73ra20. doi:10.1126/
scitranslmed.3001201 
3. Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, et al. 
Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-
peptide complexes in systemic lupus erythematosus. Sci Transl Med (2011) 
3:73ra19. doi:10.1126/scitranslmed.3001180 
4. Pham CT. Neutrophil serine proteases: specific regulators of inflammation. 
Nat Rev Immunol (2006) 6:541–50. doi:10.1038/nri1841 
5. Perera NC, Schilling O, Kittel H, Back W, Kremmer E, Jenne DE. NSP4, an 
elastase-related protease in human neutrophils with arginine specificity. Proc 
Natl Acad Sci U S A (2012) 109:6229–34. doi:10.1073/pnas.1200470109 
6. Mcguire MJ, Lipsky PE, Thiele DL. Generation of active myeloid and 
lymphoid granule serine proteases requires processing by the granule thiol 
protease dipeptidyl peptidase I. J Biol Chem (1993) 268:2458–67. 
7. Borregaard N, Sehested M, Nielsen BS, Sengelov H, Kjeldsen L. Biosynthesis 
of granule proteins in normal human bone marrow cells. Gelatinase is a 
marker of terminal neutrophil differentiation. Blood (1995) 85:812–7. 
8. Theilgaard-Monch K, Jacobsen LC, Borup R, Rasmussen T, Bjerregaard MD, 
Nielsen FC, et  al. The transcriptional program of terminal granulocytic 
differentiation. Blood (2005) 105:1785–96. doi:10.1182/blood-2004-08-3346 
9. Borregaard N. Neutrophils, from marrow to microbes. Immunity (2010) 
33:657–70. doi:10.1016/j.immuni.2010.11.011 
10. Shafer WM, Katzif S, Bowers S, Fallon M, Hubalek M, Reed MS, et al. Tailoring 
an antibacterial peptide of human lysosomal cathepsin G to enhance its 
broad-spectrum action against antibiotic-resistant bacterial pathogens. Curr 
Pharm Des (2002) 8:695–702. doi:10.2174/1381612023395376 
11. Weinrauch Y, Drujan D, Shapiro SD, Weiss J, Zychlinsky A. Neutrophil 
elastase targets virulence factors of enterobacteria. Nature (2002) 417:91–4. 
doi:10.1038/417091a 
12. Sorensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, 
et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide 
LL-37 by extracellular cleavage with proteinase 3. Blood (2001) 97:3951–9. 
doi:10.1182/blood.V97.12.3951 
13. Massberg S, Grahl L, Von Bruehl ML, Manukyan D, Pfeiler S, Goosmann C, 
et al. Reciprocal coupling of coagulation and innate immunity via neutrophil 
serine proteases. Nat Med (2010) 16:887–96. doi:10.1038/nm.2184 
14. Robertson SE, Young JD, Kitson S, Pitt A, Evans J, Roes J, et al. Expression and 
alternative processing of IL-18 in human neutrophils. Eur J Immunol (2006) 
36:722–31. doi:10.1002/eji.200535402 
15. Guma M, Ronacher L, Liu-Bryan R, Takai S, Karin M, Corr M. Caspase 
1-independent activation of interleukin-1beta in neutrophil-predominant 
inflammation. Arthritis Rheum (2009) 60:3642–50. doi:10.1002/art.24959 
16. Lefrancais E, Roga S, Gautier V, Gonzalez-De-Peredo A, Monsarrat B, Girard 
JP, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase 
and cathepsin G. Proc Natl Acad Sci U S A (2012) 109:1673–8. doi:10.1073/
pnas.1115884109 
17. Wittamer V, Bondue B, Guillabert A, Vassart G, Parmentier M, Communi D. 
Neutrophil-mediated maturation of chemerin: a link between innate and 
adaptive immunity. J Immunol (2005) 175:487–93. doi:10.4049/jimmunol. 
175.1.487 
18. Zabel BA, Allen SJ, Kulig P, Allen JA, Cichy J, Handel TM, et al. Chemerin 
activation by serine proteases of the coagulation, fibrinolytic, and inflamma-
tory cascades. J Biol Chem (2005) 280:34661–6. doi:10.1074/jbc.M504868200 
19. Padrines M, Wolf M, Walz A, Baggiolini M. Interleukin-8 processing by neu-
trophil elastase, cathepsin G and proteinase-3. FEBS Lett (1994) 352:231–5. 
doi:10.1016/0014-5793(94)00952-X 
20. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of 
the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell 
mobilization induced by GCSF or cyclophosphamide. J Clin Invest (2003) 
111:187–96. doi:10.1172/JCI15994 
21. Horwitz M, Benson KF, Person RE, Aprikyan AG, Dale DC. Mutations in 
ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic 
haematopoiesis. Nat Genet (1999) 23:433–6. doi:10.1038/70544 
22. Dale DC, Person RE, Bolyard AA, Aprikyan AG, Bos C, Bonilla MA, et al. 
Mutations in the gene encoding neutrophil elastase in congenital and cyclic 
neutropenia. Blood (2000) 96:2317–22. 
23. Nayak RC, Trump LR, Aronow BJ, Myers K, Mehta P, Kalfa T, et al. Pathogenesis 
of ELANE-mutant severe neutropenia revealed by induced pluripotent stem 
cells. J Clin Invest (2015) 125:3103–16. doi:10.1172/JCI80924 
24. Martinod K, Witsch T, Farley K, Gallant M, Remold-O’Donnell E, 
Wagner DD. Neutrophil elastase-deficient mice form neutrophil extracellular 
traps in an experimental model of deep vein thrombosis. J Thromb Haemost 
(2016) 14:551–8. doi:10.1111/jth.13239 
25. Loison F, Zhu H, Karatepe K, Kasorn A, Liu P, Ye K, et  al. Proteinase 
3- dependent caspase-3 cleavage modulates neutrophil death and inflamma-
tion. J Clin Invest (2014) 124:4445–58. doi:10.1172/JCI76246 
26. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, et al. Novel 
cell death program leads to neutrophil extracellular traps. J Cell Biol (2007) 
176:231–41. doi:10.1083/jcb.200606027 
27. Pilsczek FH, Salina D, Poon KK, Fahey C, Yipp BG, Sibley CD, et  al. 
A  novel mechanism of rapid nuclear neutrophil extracellular trap forma-
tion in response to Staphylococcus aureus. J Immunol (2010) 185:7413–25. 
doi:10.4049/jimmunol.1000675 
28. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, 
et al. Neutrophil extracellular traps kill bacteria. Science (2004) 303:1532–5. 
doi:10.1126/science.1092385 
29. Urban CF, Ermert D, Schmid M, Abu-Abed U, Goosmann C, Nacken W, 
et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein 
complex involved in host defense against Candida albicans. PLoS Pathog 
(2009) 5:e1000639. doi:10.1371/journal.ppat.1000639 
30. Rochael NC, Guimaraes-Costa AB, Nascimento MT, Desouza-Vieira TS, 
Oliveira MP, Garcia E, et al. Classical ROS-dependent and early/rapid ROS-
independent release of neutrophil extracellular traps triggered by Leishmania 
parasites. Sci Rep (2015) 5:18302. doi:10.1038/srep18302 
31. Saitoh T, Komano J, Saitoh Y, Misawa T, Takahama M, Kozaki T, et  al. 
Neutrophil extracellular traps mediate a host defense response to human 
immunodeficiency virus-1. Cell Host Microbe (2012) 12:109–16. doi:10.1016/j.
chom.2012.05.015 
32. Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, 
Yalavarthi S, Knight JS, et al. NETs are a source of citrullinated autoantigens 
and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl 
Med (2013) 5:178ra140. doi:10.1126/scitranslmed.3005580 
33. Schauer C, Janko C, Munoz LE, Zhao Y, Kienhofer D, Frey B, et al. Aggregated 
neutrophil extracellular traps limit inflammation by degrading cytokines and 
chemokines. Nat Med (2014) 20:511–7. doi:10.1038/nm.3547 
34. Warnatsch A, Ioannou M, Wang Q, Papayannopoulos V. Inflammation. 
Neutrophil extracellular traps license macrophages for cytokine production 
in atherosclerosis. Science (2015) 349:316–20. doi:10.1126/science.aaa8064 
35. Leppkes M, Maueroder C, Hirth S, Nowecki S, Gunther C, Billmeier U, 
et al. Externalized decondensed neutrophil chromatin occludes pancreatic 
ducts and drives pancreatitis. Nat Commun (2016) 7:10973. doi:10.1038/
ncomms10973 
36. Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb 
Z, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 
(2009) 15:623–5. doi:10.1038/nm.1959 
37. O’Donoghue AJ, Jin Y, Knudsen GM, Perera NC, Jenne DE, Murphy JE, et al. 
Global substrate profiling of proteases in human neutrophil extracellular 
traps reveals consensus motif predominantly contributed by elastase. PLoS 
One (2013) 8:e75141. doi:10.1371/journal.pone.0075141 
38. Yipp BG, Petri B, Salina D, Jenne CN, Scott BN, Zbytnuik LD, et al. Infection-
induced NETosis is a dynamic process involving neutrophil multitasking 
in vivo. Nat Med (2012) 18:1386–93. doi:10.1038/nm.2847 
39. Clark SR, Ma AC, Tavener SA, Mcdonald B, Goodarzi Z, Kelly MM, et al. 
Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in 
septic blood. Nat Med (2007) 13:463–9. doi:10.1038/nm1565 
40. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD 
Jr, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S 
A (2010) 107:15880–5. doi:10.1073/pnas.1005743107 
9Majewski et al. SLPI and SerpinB vs. NETs
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 261
41. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil 
 elastase and myeloperoxidase regulate the formation of neutrophil extracel-
lular traps. J Cell Biol (2010) 191:677–91. doi:10.1083/jcb.201006052 
42. Douda DN, Khan MA, Grasemann H, Palaniyar N. SK3 channel and mito-
chondrial ROS mediate NADPH oxidase-independent NETosis induced by 
calcium influx. Proc Natl Acad Sci U S A (2015) 112:2817–22. doi:10.1073/
pnas.1414055112 
43. Sorensen OE, Clemmensen SN, Dahl SL, Ostergaard O, Heegaard NH, 
Glenthoj A, et  al. Papillon-Lefevre syndrome patient reveals species- 
dependent requirements for neutrophil defenses. J Clin Invest (2014) 
124:4539–48. doi:10.1172/JCI76009 
44. Roberts H, White P, Dias I, McKaig S, Veeramachaneni R, Thakker N, et al. 
Characterization of neutrophil function in Papillon-Lefèvre syndrome. 
J Leukoc Biol (2016). doi:10.1189/jlb.5A1015-489R 
45. Wang Y, Li M, Stadler S, Correll S, Li P, Wang D, et al. Histone hypercitrulli-
nation mediates chromatin decondensation and neutrophil extracellular trap 
formation. J Cell Biol (2009) 184:205–13. doi:10.1083/jcb.200806072 
46. Bicker KL, Thompson PR. The protein arginine deiminases: structure, func-
tion, inhibition, and disease. Biopolymers (2013) 99:155–63. doi:10.1002/
bip.22127 
47. Luo Y, Arita K, Bhatia M, Knuckley B, Lee YH, Stallcup MR, et al. Inhibitors 
and inactivators of protein arginine deiminase 4: functional and structural 
characterization. Biochemistry (2006) 45:11727–36. doi:10.1021/bi061180d 
48. Neeli I, Khan SN, Radic M. Histone deimination as a response to inflam-
matory stimuli in neutrophils. J Immunol (2008) 180:1895–902. doi:10.4049/
jimmunol.180.3.1895 
49. Neeli I, Radic M. Opposition between PKC isoforms regulates histone 
deimination and neutrophil extracellular chromatin release. Front Immunol 
(2013) 4:38. doi:10.3389/fimmu.2013.00038 
50. Metzler KD, Goosmann C, Lubojemska A, Zychlinsky A, Papayannopoulos V. 
A myeloperoxidase-containing complex regulates neutrophil elastase release 
and actin dynamics during NETosis. Cell Rep (2014) 8:883–96. doi:10.1016/j.
celrep.2014.06.044 
51. Sallenave JM, Si Tahar M, Cox G, Chignard M, Gauldie J. Secretory leukocyte 
proteinase inhibitor is a major leukocyte elastase inhibitor in human neutro-
phils. J Leukoc Biol (1997) 61:695–702. 
52. Farley K, Stolley JM, Zhao P, Cooley J, Remold-O’Donnell E. A serpinB1 
regulatory mechanism is essential for restricting neutrophil extracellular 
trap generation. J Immunol (2012) 189:4574–81. doi:10.4049/jimmunol. 
1201167 
53. Zabieglo K, Majewski P, Majchrzak-Gorecka M, Wlodarczyk A, Grygier B, 
Zegar A, et al. The inhibitory effect of secretory leukocyte protease inhibitor 
(SLPI) on formation of neutrophil extracellular traps. J Leukoc Biol (2015) 
98:99–106. doi:10.1189/jlb.4AB1114-543R 
54. Gettins PG. Serpin structure, mechanism, and function. Chem Rev (2002) 
102:4751–804. doi:10.1021/cr010170 
55. Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: 
structure, function, and regulation. J Biol Chem (1994) 269:15957–60. 
56. Izuhara K, Ohta S, Kanaji S, Shiraishi H, Arima K. Recent progress in under-
standing the diversity of the human ov-serpin/clade B serpin family. Cell Mol 
Life Sci (2008) 65:2541–53. doi:10.1007/s00018-008-8049-7 
57. Remold-O’Donnell E, Nixon JC, Rose RM. Elastase inhibitor. Characterization 
of the human elastase inhibitor molecule associated with monocytes, 
macrophages, and neutrophils. J Exp Med (1989) 169:1071–86. doi:10.1084/
jem.169.3.1071 
58. Sugimori T, Cooley J, Hoidal JR, Remold-O’Donnell E. Inhibitory properties 
of recombinant human monocyte/neutrophil elastase inhibitor. Am J Respir 
Cell Mol Biol (1995) 13:314–22. doi:10.1165/ajrcmb.13.3.7654387 
59. Benarafa C, Cooley J, Zeng W, Bird PI, Remold-O’Donnell E. Characterization 
of four murine homologs of the human ov-serpin monocyte neutrophil 
elastase inhibitor MNEI (SERPINB1). J Biol Chem (2002) 277:42028–33. 
doi:10.1074/jbc.M207080200 
60. Cooley J, Takayama TK, Shapiro SD, Schechter NM, Remold-O’Donnell E. 
The serpin MNEI inhibits elastase-like and chymotrypsin-like serine 
proteases through efficient reactions at two active sites. Biochemistry (2001) 
40:15762–70. doi:10.1021/bi0113925 
61. Yasumatsu R, Altiok O, Benarafa C, Yasumatsu C, Bingol-Karakoc G, 
Remold-O’Donnell E, et  al. SERPINB1 upregulation is associated with 
in  vivo complex formation with neutrophil elastase and cathepsin G in a 
baboon model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol 
Physiol (2006) 291:L619–27. doi:10.1152/ajplung.00507.2005 
62. Torriglia A, Perani P, Brossas JY, Chaudun E, Treton J, Courtois Y, et  al. 
L-DNase II, a molecule that links proteases and endonucleases in apoptosis, 
derives from the ubiquitous serpin leukocyte elastase inhibitor. Mol Cell Biol 
(1998) 18:3612–9. doi:10.1128/MCB.18.8.4947 
63. Padron-Barthe L, Lepretre C, Martin E, Counis MF, Torriglia A. 
Conformational modification of serpins transforms leukocyte elastase 
inhibitor into an endonuclease involved in apoptosis. Mol Cell Biol (2007) 
27:4028–36. doi:10.1128/MCB.01959-06 
64. Popova EY, Claxton DF, Lukasova E, Bird PI, Grigoryev SA. Epigenetic het-
erochromatin markers distinguish terminally differentiated leukocytes from 
incompletely differentiated leukemia cells in human blood. Exp Hematol 
(2006) 34:453–62. doi:10.1016/j.exphem.2006.01.003 
65. Doumas S, Kolokotronis A, Stefanopoulos P. Anti-inflammatory and antimi-
crobial roles of secretory leukocyte protease inhibitor. Infect Immun (2005) 
73:1271–4. doi:10.1128/IAI.73.3.1271-1274.2005 
66. Moreau T, Baranger K, Dade S, Dallet-Choisy S, Guyot N, Zani ML. 
Multifaceted roles of human elafin and secretory leukocyte proteinase 
inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. 
Biochimie (2008) 90:284–95. doi:10.1016/j.biochi.2007.09.007 
67. Majchrzak-Gorecka M, Majewski P, Grygier B, Murzyn K, Cichy J. Secretory 
leukocyte protease inhibitor (SLPI), a multifunctional protein in the host 
defense response. Cytokine Growth Factor Rev (2016) 28:79–93. doi:10.1016/j.
cytogfr.2015.12.001 
68. Vogelmeier C, Gillissen A, Buhl R. Use of secretory leukoprotease inhibitor 
to augment lung antineutrophil elastase activity. Chest (1996) 110:261S–6S. 
doi:10.1378/chest.110.6_Supplement.261S 
69. Xu W, He B, Chiu A, Chadburn A, Shan M, Buldys M, et  al. Epithelial 
cells trigger frontline immunoglobulin class switching through a pathway 
regulated by the inhibitor SLPI. Nat Immunol (2007) 8:294–303. doi:10.1038/
ni1434 
70. Boudier C, Bieth JG. The proteinase: mucus proteinase inhibitor binding 
stoichiometry. J Biol Chem (1992) 267:4370–5. 
71. Jacobsen LC, Sorensen OE, Cowland JB, Borregaard N, Theilgaard-Monch K. 
The secretory leukocyte protease inhibitor (SLPI) and the secondary granule 
protein lactoferrin are synthesized in myelocytes, colocalize in subcellular 
fractions of neutrophils, and are coreleased by activated neutrophils. J Leukoc 
Biol (2008) 83:1155–64. doi:10.1189/jlb.0706442 
72. Klimenkova O, Ellerbeck W, Klimiankou M, Unalan M, Kandabarau  S, 
Gigina A, et  al. A lack of secretory leukocyte protease inhibitor (SLPI) 
causes defects in granulocytic differentiation. Blood (2014) 123:1239–49. 
doi:10.1182/blood-2013-06-508887 
73. Subramaniyam D, Hollander C, Westin U, Erjefalt J, Stevens T, Janciauskiene S. 
Secretory leukocyte protease inhibitor inhibits neutrophil apoptosis. 
Respirology (2011) 16:300–7. doi:10.1111/j.1440-1843.2010.01901.x 
74. Knight JS, Carmona-Rivera C, Kaplan MJ. Proteins derived from neu-
trophil extracellular traps may serve as self-antigens and mediate organ 
damage in autoimmune diseases. Front Immunol (2012) 3:380. doi:10.3389/
fimmu.2012.00380 
75. Wright HL, Moots RJ, Edwards SW. The multifactorial role of neutrophils in 
rheumatoid arthritis. Nat Rev Rheumatol (2014) 10:593–601. doi:10.1038/
nrrheum.2014.80 
76. Dwivedi N, Upadhyay J, Neeli I, Khan S, Pattanaik D, Myers L, et al. Felty’s 
syndrome autoantibodies bind to deiminated histones and neutrophil extra-
cellular chromatin traps. Arthritis Rheum (2012) 64:982–92. doi:10.1002/
art.33432 
77. Darrah E, Andrade F. NETs: the missing link between cell death and 
systemic autoimmune diseases? Front Immunol (2013) 3:428. doi:10.3389/
fimmu.2012.00428 
78. Dwivedi N, Radic M. Citrullination of autoantigens implicates NETosis in the 
induction of autoimmunity. Ann Rheum Dis (2014) 73:483–91. doi:10.1136/
annrheumdis-2013-203844 
79. Hakkim A, Furnrohr BG, Amann K, Laube B, Abu Abed U, Brinkmann V, 
et al. Impairment of neutrophil extracellular trap degradation is associated 
with lupus nephritis. Proc Natl Acad Sci U S A (2010) 107(21):9813–8. 
doi:10.1073/pnas.0909927107 
80. Skrzeczynska-Moncznik J, Wlodarczyk A, Zabieglo K, Kapinska-Mrowiecka M, 
Marewicz E, Dubin A, et al. Secretory leukocyte proteinase inhibitor-competent 
10
Majewski et al. SLPI and SerpinB vs. NETs
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 261
DNA deposits are potent stimulators of plasmacytoid dendritic cells: implication 
for psoriasis. J Immunol (2012) 189:1611–7. doi:10.4049/jimmunol. 
1103293 
81. Skrzeczynska-Moncznik J, Wlodarczyk A, Banas M, Kwitniewski M, 
Zabieglo  K, Kapinska-Mrowiecka M, et  al. DNA structures decorated 
with cathepsin G/secretory leukocyte proteinase inhibitor stimulate IFNI 
production by plasmacytoid dendritic cells. Am J Clin Exp Immunol (2013) 
2:186–94. 
82. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of 
psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 
(2012) 133:377–85. doi:10.1038/jid.2012.339 
83. Chandran V. The genetics of psoriasis and psoriatic arthritis. Clin Rev Allergy 
Immunol (2013) 44:149–56. doi:10.1007/s12016-012-8303-5 
84. Grozdev I, Korman N, Tsankov N. Psoriasis as a systemic disease. Clin 
Dermatol (2014) 32:343–50. doi:10.1016/j.clindermatol.2013.11.001 
85. Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu 
Rev Immunol (2014) 32:227–55. doi:10.1146/annurev-immunol-032713- 
120225 
86. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immuno-
pathogenesis of psoriasis. J Invest Dermatol (2009) 129:1339–50. doi:10.1038/
jid.2009.59 
87. Boyman O, Conrad C, Tonel G, Gilliet M, Nestle FO. The pathogenic role of 
tissue-resident immune cells in psoriasis. Trends Immunol (2007) 28:51–7. 
doi:10.1016/j.it.2006.12.005 
88. Albanesi C, Scarponi C, Pallotta S, Daniele R, Bosisio D, Madonna S, et al. 
Chemerin expression marks early psoriatic skin lesions and correlates with 
plasmacytoid dendritic cell recruitment. J Exp Med (2009) 206:249–58. 
doi:10.1084/jem.20080129 
89. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid 
dendritic cell precursors. Annu Rev Immunol (2005) 23:275–306. doi:10.1146/
annurev.immunol.23.021704.115633 
90. Fuchsberger M, Hochrein H, O’Keeffe M. Activation of plasmacytoid 
dendritic cells. Immunol Cell Biol (2005) 83:571–7. doi:10.1111/j.1440- 
1711.2005.01392.x 
91. Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all 
roads lead to type I interferons. Curr Opin Immunol (2006) 18:676–82. 
doi:10.1016/j.coi.2006.09.014 
92. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. 
Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha 
production. J Exp Med (2005) 202:135–43. doi:10.1084/jem.20050500 
93. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, et al. 
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial 
peptide. Nature (2007) 449:564–9. doi:10.1038/nature06116 
94. Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, et al. 
Self-RNA-antimicrobial peptide complexes activate human dendritic cells 
through TLR7 and TLR8. J Exp Med (2009) 206:1983–94. doi:10.1084/
jem.20090480 
95. Caielli S, Athale S, Domic B, Murat E, Chandra M, Banchereau R, et  al. 
Oxidized mitochondrial nucleoids released by neutrophils drive type I inter-
feron production in human lupus. J Exp Med (2016) 213:697. doi:10.1084/
jem.20151876 
96. Lood C, Blanco LP, Purmalek MM, Carmona-Rivera C, De Ravin SS, 
Smith CK, et al. Neutrophil extracellular traps enriched in oxidized mito-
chondrial DNA are interferogenic and contribute to lupus-like disease. Nat 
Med (2016) 22:146–53. doi:10.1038/nm.4027 
97. Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and 
persists longer than nuclear DNA damage in human cells following oxidative 
stress. Proc Natl Acad Sci U S A (1997) 94:514–9. doi:10.1073/pnas.94.2.514 
98. Yousefi S, Mihalache C, Kozlowski E, Schmid I, Simon HU. Viable neutro-
phils release mitochondrial DNA to form neutrophil extracellular traps. Cell 
Death Differ (2009) 16:1438–44. doi:10.1038/cdd.2009.96 
99. Cichy J, Potempa J, Chawla RK, Travis J. Stimulatory effect of inflammatory 
cytokines on alpha 1-antichymotrypsin expression in human lung-derived 
epithelial cells. J Clin Invest (1995) 95:2729–33. doi:10.1172/JCI117975 
100. Cichy J, Potempa J, Travis J. Biosynthesis of alpha1-proteinase inhibitor 
by human lung-derived epithelial cells. J Biol Chem (1997) 272:8250–5. 
doi:10.1074/jbc.272.13.8250 
101. Schmidt NW, Jin F, Lande R, Curk T, Xian W, Lee C, et al. Liquid-crystalline 
ordering of antimicrobial peptide-DNA complexes controls TLR9 activation. 
Nat Mater (2015) 14:696–700. doi:10.1038/nmat4298 
102. Wingens M, Van Bergen BH, Hiemstra PS, Meis JF, Van Vlijmen-Willems IM, 
Zeeuwen PL, et  al. Induction of SLPI (ALP/HUSI-I) in epidermal kerati-
nocytes. J Invest Dermatol (1998) 111:996–1002. doi:10.1046/j.1523-1747. 
1998.00425.x 
103. Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E, et  al. 
Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in mono-
cytes and inhibits p65 binding. J Exp Med (2005) 202:1659–68. doi:10.1084/
jem.20050768 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Majewski, Majchrzak-Gorecka, Grygier, Skrzeczynska-Moncznik, 
Osiecka and Cichy. This is an open-access article distributed under the terms of the 
Creative Commons Attribution License (CC BY). The use, distribution or reproduc-
tion in other forums is permitted, provided the original author(s) or licensor are 
credited and that the original publication in this journal is cited, in accordance with 
accepted academic practice. No use, distribution or reproduction is permitted which 
does not comply with these terms.
